A practical reference on retatrutide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-12. Anything still debated is marked as such rather than presented as settled.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| Common matrix | Plasma or serum | Collected under controlled conditions |
| Primary method | Liquid chromatography–tandem mass spectrometry | Structural specificity |
| Alternative method | Immunoassay | Lower specificity, higher throughput |
| Reporting unit | ng/mL | Concentration in matrix |
| Key validation item | Selectivity | Interference from related peptides |
As a peptide, the compound is generally supplied as a lyophilized powder and stored frozen to slow degradation. Recommended conditions usually sit at minus twenty degrees Celsius or colder, shielded from light and moisture. Solutions are less stable than the dry powder and are often prepared fresh before analysis. Repeated freeze-thaw cycles can drive aggregation, so splitting stock material into small aliquots reduces handling stress and preserves sample integrity.
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Although Calderón's strategy intended to end violence between rival cartels, critics argue that it worsened the conflict. By removing cartel leaders through arrests or killings, his administration created leadership vacuums that sparked internal power struggles and greater competition between cartels. Balance of power shifts meant that new cartels emerged as other groups weakened, for example, the fragmentation of La Familia Michoacana, which gave rise to the Knights Templar Cartel. Splintered cartels fought to exploit overlapping patches of smuggling routes and territories, and also sought to manipulate the system by leaking intelligence to Mexican authorities or the U.S. Drug Enforcement Administration (DEA) to turn law enforcement against their rivals, using knowledge from the groups they had broken away from. During Calderón's presidential term, the murder rate of Mexico increased dramatically. Annual homicides rose from more than 5,000 in 2008 to 9,600 in 2009 and over 15,000 in 2010. By the end of Calderón's presidency, his administration's statistics claimed that, during his six-year term, 50,000 drug-related homicides occurred. Outside sources claimed more than 120,000 murders happened in the same period as a result of Calderón's strategy. Some analysts, including U.S. Ambassador in Mexico Carlos Pascual, argued that this increase was a direct result of Calderón's military measures.
Other requirements considered when designing operando experiments include reagent and product flow rates, catalyst position, beam paths, and window positions and sizes. All of these factors must also be accounted for while designing operando experiments, as the spectroscopic techniques used may alter the reaction conditions. An example of this was reported by Tinnemans et al., which noted that local heating by a Raman laser can give spot temperatures exceeding 100 °C. Also, Meunier reports that when using DRIFTS, there is a noticeable temperature difference (on the order of hundreds of degrees) between the crucible core and the exposed surface of the catalyst due to losses caused by the IR-transparent windows necessary for analysis.
RO5203648 is a trace amine-associated receptor 1 (TAAR1) partial agonist. It is a potent and highly selective partial agonist of both rodent and primate TAAR1. The drug suppresses the effects of psychostimulants like cocaine and methamphetamine. It also produces a variety of other behavioral effects, such as antidepressant-like, antipsychotic-like, and antiaddictive effects. Research with RO5203648 has led to interest in TAAR1 agonists for potential treatment of drug addiction. RO5203648 itself was not developed for potential medical use due to poor expected human pharmacokinetics.
Hodgkinsine is an alkaloid found in plants of the genus Psychotria, particularly Psychotria colorata, although it is also found in Psychotria lyciiflora and probably other species in this family, Hodgkinsine has antiviral, antibacterial and antifungal effects, but has mainly been researched for the analgesic effects that it produces, and is thought to be one of the components responsible for the analgesic effects seen when Psychotria colorata is used in traditional medical practice in humans. It has been found to act as both a mu opioid agonist and an NMDA antagonist, both of which are mechanisms of action shared with commonly used painkillers (morphine and ketamine respectively, and which occur concurrently in the clinical analgesics methadone and levorphanol). Hodgkinsine is a trimer composed of three pyrrolidinoindoline subunits, with the monomer closely resembling another alkaloid eseroline which has similar bioactivity. Due to its complex structure and multiple chiral centres, hodgkinsine has many stereoisomers and significant research has been undertaken to elucidate the structure-activity relationships of the various isomers and synthetic derivatives structurally derived from hodgkinsine.
In 2013, as part of "Operation Swill", investigators in New Jersey raided 17 TGI Fridays franchised restaurants owned by The Briad Group. They found that the bars were replacing premium brand alcoholic beverages with lower-cost brands yet charging patrons for the more expensive liquor. In 2018, a tipping policy change prompted strikes across TGI Fridays restaurants in the United Kingdom as waiting staff took issue with a decision to redistribute 20% of customer tips paid by card to kitchen staff in lieu of a raise. In 2022, during the Russian invasion of Ukraine, TGI Fridays was criticized by Jeffrey Sonnenfeld of Yale for "digging in" (defying demands for exit or reduction of activities). TGI Fridays issued a statement saying that it stood with the people of Ukraine, that the decision whether to close was for local franchisees to make, and that any proceeds received would be donated to Mercy Chefs, an organisation supporting humanitarian efforts in Ukraine. In 2022, the US restaurants faced a class-action lawsuit over the content of the TGI Fridays-branded mozzarella stick snack food manufactured by Inventure Foods, sold in grocery stores. Litigants claimed the extruded corn snacks contained no mozzarella cheese. Inventure Foods settled the claims for $900,000, agreeing to pay up to $6 per household, in February 2024.
Sources: en.wikipedia.org
In 1977, Migita published further work on the coupling of allyl-tin reagents with both aryl (C) and acyl (D) halides. The greater ability of allyl groups to migrate to the palladium catalyst allowed the reactions to be performed at lower temperatures. Yields for aryl halides ranged from 4% to 100%, and for acyl halides from 27% to 86%. Reflecting the early contributions of Migita and Kosugi, the Stille reaction is sometimes called the Migita–Kosugi–Stille coupling.
A similar promotion was held in September 2011, near the start of a traditional school year, encouraging the use of the game as an educational tool for science and mathematics. Valve wrote that they felt that Portal "makes physics, math, logic, spatial reasoning, probability, and problem-solving interesting, cool, and fun", a necessary feature to draw children into learning. This was tied to Digital Promise, a United States Department of Education initiative to help develop digital tools for education, which Valve is part of. Portal: Still Alive was announced for Xbox Live Arcade at the 2008 E3 convention, and was released on October 22, 2008. It features the original game, 14 new challenges, and new achievements. The additional content was based on levels from the map pack Portal: The Flash Version created by We Create Stuff and contains no additional story-related levels. According to Valve spokesman Doug Lombardi, Microsoft had previously rejected Portal on the platform due to its large size. Portal: Still Alive was well received by reviewers. 1UP.com's Andrew Hayward stated that, with the easier access and lower cost than paying for The Orange Box, Portal is now "stronger than ever". IGN editor Cam Shea ranked it fifth on his top 10 list of Xbox Live Arcade games. He stated that it was debatable whether an owner of The Orange Box should purchase this, as its added levels do not add to the plot. However, he praised the quality of the new maps included. The game ranked 7th in a later list of top Xbox Live Arcade titles compiled by IGN's staff in September 2010.
To determine the pore diameter, physical methods such as porosimeter (mercury, liquid-liquid porosimeter and Bubble Point Test) are also used, but a certain form of the pores (such as cylindrical or concatenated spherical holes) is assumed. Such methods are used for membranes whose pore geometry does not match the ideal, and we get "nominal" pore diameter, which characterizes the membrane, but does not necessarily reflect its actual filtration behavior and selectivity. The selectivity is highly dependent on the separation process, the composition of the membrane and its electrochemical properties in addition to the pore size. With high selectivity, isotopes can be enriched (uranium enrichment) in nuclear engineering or industrial gases like nitrogen can be recovered (gas separation). Ideally, even racemics can be enriched with a suitable membrane. When choosing membranes selectivity has priority over a high permeability, as low flows can easily be offset by increasing the filter surface with a modular structure. In gas phase filtration different deposition mechanisms are operative, so that particles having sizes below the pore size of the membrane can be retained as well.
=== Availability === The "reference" version of BLOSUM is found in the NCBI toolkits. Both the older (deprecated) NCBI C Toolkit and the current NCBI C++ Toolkit provide the BLOSUM45, BLOSUM50, BLOSUM62, BLOSUM80, and BLOSUM90 matrices. Both also offer APIs for making use of the matrices. The original source code for calculating BLOSUM is also found on the NCBI website, at https://ftp.ncbi.nih.gov/repository/blocks/unix/blosum/. This archive "blosum.tar.Z" represents the original miscalculated version with improved search performance from 1992. The archive also contains pre-calculated BLOSUM outputs at the following similarity levels: "-2" (blosumn), 30, 40, 45, 50, 55, 60, 62, 65, 70, 75, 80, 85, 90, 95, and 100.
Black and Hispanic women are at higher risk for isoniazid-induced hepatotoxicity. When it happens, isoniazid-induced liver toxicity has been shown to occur in 50% of patients within the first 2 months of therapy. Some recommend that liver function should be monitored carefully in all people receiving it, but others recommend monitoring only in certain populations. Headache, poor concentration, weight gain, poor memory, insomnia, and depression have all been associated with isoniazid use. All patients and healthcare workers should be aware of these serious side effects, especially if suicidal ideation or behavior are suspected.
Sources: en.wikipedia.org
== Welfare considerations during farmed insect rearing == As with other livestock animals, a variety of welfare concerns can manifest during the rearing and slaughter of insects. The 5 Domains framework can be used to broadly categorize these areas of possible concern into four functional domains (nutrition, environment, behavior, and physical health) which then influence the mental domain of the animal's welfare state. As the insect industry is very new, and there are few animal welfare scientists dedicated to studying its livestock, there is little guidance or infrastructure dedicated to improving farmed insect welfare. Further, just as with farmed vertebrates, species-specific guidance is needed to maintain high welfare for each species of insects that is farmed. Recently, several comprehensive and open access review papers have been published that cover the likely welfare concerns for black soldier flies (Hermetia illucens), yellow mealworms (Tenebrio molitor), and three species of farmed crickets (Acheta domesticus, Gryllus bimaculatus, Gryllodes sigillatus), as well as some work on the housefly (Musca domestica). The major, currently known areas of welfare concern during rearing are organized below by functional domain and largely focus on the most farmed insects: black soldier flies, yellow mealworms, and farmed crickets.
== History == The company was incorporated in January 2006 as Phluid, Inc. and changed its name to Tandem Diabetes Care in 2008. Former Biosite executive Kim Blickenstaff joined as president and chief executive officer in 2007. Its first product was designed following interviews with pump users and clinicians and used a color touchscreen rather than the button-based interfaces then common on insulin pumps. The Food and Drug Administration (FDA) cleared the t:slim insulin-delivery system in November 2011, and Tandem began selling it in the United States the following year. In November 2013, Tandem sold eight million shares at $15 each in its initial public offering, raising approximately $108 million after costs. Tandem began shipping the software-updatable t:slim X2 in 2016. The FDA subsequently authorized versions that displayed readings from the Dexcom G5 and G6 CGMs, and in 2019 classified the t:slim X2 as the first alternate controller enabled insulin pump, a category designed to support interoperable diabetes devices. John Sheridan, previously the company's chief operating officer, succeeded Blickenstaff as president and CEO in March 2019. The company acquired the diabetes-data application Sugarmate in June 2020. It acquired infusion-set developer Capillary Biomedical for $24.7 million in July 2022 and Swiss patch-pump developer AMF Medical in January 2023. AMF had been developing Sigi, a rechargeable patch pump that used prefilled insulin cartridges; the product remained in development at the end of 2025.
=== Geelong Football Club (2000–2010) === Thompson was appointed as Geelong Football Club senior coach at the end of the 1999 season, for the 2000 season when he replaced Gary Ayres, who quit as Geelong Football Club senior coach. Thompson as Geelong Football Club senior coach was given an extended time to rebuild the club's playing list. Geelong under Thompson finished 5th in the 2000 season in his first season as senior coach but was eliminated by 8th placed Hawthorn in the first week of the finals in the first finals match ever held at the Docklands Stadium. The club under Thompson performed poorly for the next three seasons from 2001 until 2003, missing the top 8 and not making the finals. Thompson's position looked in danger, but in the 2004 season, Geelong under Thompson was a big improver, finishing fourth and making the Preliminary Finals, losing to eventual runners-up Brisbane Lions. Due to his success in reinvigorating the club, Thompson's contract was extended until 2007. The following year in the 2005 season, the club under Thompson finished sixth and was beaten in the Semi-Finals by 3 points against the eventual premiers Sydney Swans after leading for the majority of the match. In the 2006 season, however the club under Thompson eventually missed the finals after winning the NAB Cup and winning their first two matches in convincing style, leading them into flag favouritism. It was also a season where Thompson had used the 2005 semi-final loss to the Swans as motivation.
== Mechanism == Seborrhoeic dermatitis is a complex condition with many interacting factors that are not yet fully explained. In general, the major factors that influence the development and severity include Malassezia yeast present on and in the skin, skin production of oily sebum, and a subsequent inflammatory response against Malassezia and their byproducts. Additional factors involved in the condition are a compromised skin barrier, the makeup and amount of sebum produced, the character of the immune response and inflammation, and the presence of other microbe species inhabiting the skin. A suggested series of events leading to seborrhoeic dermatitis is an initially damaged skin barrier and abnormal sebum production, which leads to a change in the microbiome of the skin that in turn elicits an immune response. An alternative explanation is an increase in sebum production feeding an increase in the Malassezia population that instigates inflammation; the inflammation then causes cellular changes that damage the skin barrier. This barrier disruption then encourages additional Malassezia growth and inflammation and again worsens skin barrier function.
The four substrates of this enzyme are 24S-hydroxycholesterol, reduced nicotinamide adenine dinucleotide phosphate (NADPH), oxygen, and a proton. Its products are (24S)-7α,24-dihydroxycholesterol, oxidised NADP+, and water. This enzyme is a cytochrome P450-type oxidoreductase, acting on paired donors, with molecular oxygen as oxidant and incorporating one of its atoms. The systematic name of this enzyme class is (24R)-cholest-5-ene-3beta,24-diol,NADPH:oxygen oxidoreductase (7alpha-hydroxylating). Other names in common use include 24-hydroxycholesterol 7alpha-monooxygenase, CYP39A1, and CYP39A1 oxysterol 7alpha-hydroxylase.
Sources: en.wikipedia.org
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.
Mass spectrometry identifies molecules by mass-to-charge transitions, which reduces interference from related peptides. Immunoassays run faster but can cross-react. Structural confirmation usually requires the mass spectrometric approach.
Cardiovascular outcomes, long-term safety, and weight regain after stopping treatment are unresolved. These questions need years of follow-up data. Published evidence covers only limited treatment durations.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.